Seer, Inc.
Seer, Inc. (NASDAQ: SEER) is a proteomics company headquartered in Redwood City, California. Founded in 2017 by Omid Farokhzad, Philip Ma, and Robert Langer, building on nanoparticle research from Harvard Medical School and Brigham and Women's Hospital, Seer develops the Proteograph Product Suite — a nanoparticle-based platform for unbiased, large-scale plasma proteomics. The technology can detect over 36,000 proteins and 300,000+ peptides per sample, offering roughly tenfold greater protein coverage than standard mass-spectrometry workflows. Seer's platform supports biomarker discovery, GWAS-driven target identification, and drug development research across pharmaceutical, academic, and clinical research settings. The company completed its Nasdaq IPO in December 2020.
Danyel Biotech represents Seer's Proteograph proteomics platform in Israel, providing local sales and application support.
- Proteomics
- Biomarker Discovery
- Plasma Proteome Analysis
- Drug Development Research
ISO 27001 (Information Security Management), ISO 13485 (Medical Device Quality Management)
Sales Contacts
Categories
Frequently Asked Questions
Who represents Seer's Proteograph platform in Israel?
Danyel Biotech represents Seer's Proteograph proteomics platform in Israel, providing local sales and application support.
What does Seer's Proteograph platform do?
The Proteograph Product Suite enables unbiased, large-scale plasma proteomics, detecting over 36,000 proteins per sample for biomarker discovery and drug development research.